Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesBiologics registers in RA: methodological aspects, current role and future applications.High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses.The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeAbatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice.Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis.Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.Current immunotherapy in rheumatoid arthritis.Adalimumab in the treatment of rheumatoid arthritis.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexateEight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Factors affecting discontinuation of adalimumab and etanercept therapy in anti-TNF-naïve patients with ankylosing spondylitis: Nationwide population-based cohort study.Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).Quality indicators as a tool in improving the introduction of new medicines.Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.Etanercept in the treatment of rheumatoid arthritis.Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databasesA Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
P2860
Q26778600-F089BC04-2528-42E2-921B-4C6E96ABDC1BQ30234303-CEA9BFAE-D4E4-4678-9D16-0D35507C1E29Q30662067-78DC018E-EC91-4EE2-A48C-0C97286C422DQ31021097-EB09338F-F7AA-4DEB-963A-0B6C494915A2Q31090015-4E35C770-F2F4-4604-B8C6-14093AFF2A92Q33775593-982A67AE-2BB9-4FFF-9E7F-D111C6E4122EQ33876826-2FD1388F-AF9C-47F4-B151-7CD9111F14C3Q33876980-1024E282-21D4-42FA-8B8A-32C8EE6FA256Q35514655-3E841FE9-254C-40F8-86CE-755FD6C4F4DFQ36099620-AD81E6A7-D165-4A2A-A810-F0E1481CF9FEQ36575283-24A22AB9-0709-48DD-ABC9-907C01927B14Q37538469-E671976F-E319-429B-AF1F-57996F1497A8Q37562571-E87D9D0F-F36B-4174-8B6C-527154A6D2F3Q38133655-AEF67BD3-B54A-4A27-9FE7-9B0259EB8E69Q38192659-4FFD9969-307F-45BE-BF2D-809F84C3FAE2Q38207759-FA9B5EAD-1AF1-42FF-8ECA-7A5F5FC66897Q38222900-1567518C-AC18-4362-9F0B-3A8A6D9BDBEBQ38238931-F4CEB07C-DFD4-4469-8ABF-D1703D5D3BC9Q38285316-8362946C-EC69-4BFC-9126-80DDF2A9184CQ38406712-77417841-9442-4AE8-AB72-34C1190BAE56Q38637585-7AB9D1B0-C5A8-4D44-81DE-799C60A848FCQ38915704-86034ABD-A157-4C63-865F-8C7BAC213255Q39702204-5AC65C81-C9EB-465A-993B-180341618F9FQ40179378-79C30319-92D9-47BC-89F5-14A11D4A3857Q40372208-3E0E32CF-BC77-4892-8AAF-9F6F063A5FACQ40556448-01DB0A44-284C-48B1-9258-0E4EE79CA0FBQ40947082-1392CD6C-2731-48D4-81AE-B2729383C02DQ41348100-3B398B50-63E4-44BB-BF80-112AF83E65BDQ43444262-22B91384-B343-4AC2-A660-E189D9A20F40Q44020347-E3EBF24D-3DAF-48B2-8106-5E866E09C827Q44695835-23943515-26C2-4482-AF3C-980EB695959EQ47380976-28C2B31D-F6AB-444E-826E-783A73FE2859Q51036235-4B151A43-168C-4593-B3A8-CBCE68A24396Q52841141-C7A04D53-84DE-4CC4-A9FB-53E96EE01C53Q58750029-350C0F22-B842-4485-809D-705B758D468EQ58800375-341FA222-5E1F-4CF3-80F5-4A37D3351809
P2860
Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors
description
article
@en
im April 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2012
@uk
name
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@en
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@nl
type
label
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@en
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@nl
prefLabel
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@en
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@nl
P2093
P50
P356
P1476
Longterm Retention of Tumor Ne ...... ry: An Appraisal of Predictors
@en
P2093
A. GIARDINA
A. MARCHESONI
A. Mathieu
C. BOTSIOS
E. GREMESE
F. Cantini
F. IANNONE
P304
P356
10.3899/JRHEUM.111125
P407
P50
P577
2012-04-01T00:00:00Z